Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
Name:
36283120.pdf
Size:
754.7Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Bennink, H.Krijgh, J.
Egberts, J. F. M.
Slootweg, M.
van Melick, H. H. E.
Roos, E. P. M.
Somford, D. M.
Zimmerman, Y.
Schultz, I. J.
Clarke, Noel W
van Moorselaar, R. J. A.
Debruyne, F. M. J.
Affiliation
Pantarhei Oncology, Zeist, The NetherlandsIssue Date
2022
Metadata
Show full item recordAbstract
The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major undesired effects of ADT is the concomitant loss of E2, causing among others an increased bone turnover and bone loss and an increased risk of osteoporosis and fractures. Therefore, the guidelines for ADT indicate to combine ADT routinely with bone-sparing agents such as bisphosphonates, denosumab or selective estrogen receptor modulators. However, these compounds may have side effects and some require inconvenient parenteral administration. Co-treatment with estrogens is an alternative approach to prevent bone loss and at the same time, to avoid other side effects caused by the loss of estrogens, which is the topic explored in the present narrative review. Estrogens investigated in PCa patients include parenteral or transdermal E2, diethylstilbestrol (DES), and ethinylestradiol (EE) as monotherapy, or high-dose estetrol (HDE4) combined with ADT. Cardiovascular adverse events have been reported with parenteral E2, DES and EE. Encouraging effects on bone parameters have been obtained with transdermal E2 (tE2) and HDE4, in the tE2 development program (PATCH study), and in the LHRHa/HDE4 co-treatment study (PCombi), respectively. Confirmation of the beneficial effects of estrogen therapy with tE2 or HDE4 on bone health in patients with advanced PCa is needed, with special emphasis on bone mass and fracture rate.Citation
Bennink H, Krijgh J, Egberts JFM, Slootweg M, van Melick HHE, Roos EPM, et al. Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review. Endocrine Connections. 2022 Dec;11(12). PubMed PMID: WOS:000904170800002.Journal
Endocrine ConnectionsDOI
10.1530/EC-22-0182PubMed ID
36283120Additional Links
https://dx.doi.org/10.1530/EC-22-0182Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1530/EC-22-0182
Scopus Count
Collections
Related articles
- Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).
- Authors: Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, Debruyne FMJ
- Issue date: 2021 Jun
- Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study.
- Authors: Zimmerman Y, Frydenberg M, van Poppel H, van Moorselaar RJA, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Krijgh J, Debruyne FMJ, Coelingh Bennink HJT
- Issue date: 2022 Nov
- The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males.
- Authors: Coelingh Bennink HJT, Prowse A, Egberts JFM, Debruyne FMJ, Huhtaniemi IT, Tombal B
- Issue date: 2024 May 23
- A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design.
- Authors: Gilbert DC, Nankivell M, Rush H, Clarke NW, Mangar S, Al-Hasso A, Rosen S, Kockelbergh R, Sundaram SK, Dixit S, Laniado M, McPhail N, Shaheen A, Brown S, Gale J, Deighan J, Marshall J, Duong T, Macnair A, Griffiths A, Amos CL, Sydes MR, James ND, Parmar MKB, Langley RE
- Issue date: 2024 Jan
- Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
- Authors: Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, Kanaga-Sundaram S, Dixit S, Laniado M, Madaan S, Collins G, Pope A, Welland A, Nankivell M, Wassersug R, Parmar MK, Langley RE, Abel PD
- Issue date: 2017 May